Major League Lacrosse Partners with Biodesix
Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.
254 Results
Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.
Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers.
In the retrospective study, mass spectrometry-based proteomic analysis was performed on pretreatment sera derived from advanced NSCLC patients who were treated with nivolumab as part of routine clinical care.
Biodesix has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. Learn more about the testing program.
Biodesix, Inc. today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24.
The Big Ten Conference has entered into strategic partnerships with Biodesix, Inc., a leading diagnostic company with a focus on lung disease, and Quidel Corporation, the manufacturer of the FDA-authorized SOFIA 2 SARS rapid antigen test.
Biodesix today announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors. Learn more!
The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO), and American Association for Cancer Research (AACR).
The Biodesix SARS-CoV-2 ddPCR™ Test detects COVID-19 with greater sensitivity than other available tests, and is now accessible by appointment at drive-up locations in Boulder and Erie.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced that it has collaborated with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.